Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Janssen

- PMLiVE

Promising new agents for multiple myeloma

Drug development for this type of bone marrow cancer has been gaining momentum, with two new proteasome inhibitor approvals in the last year alone and a number of new treatments...

- PMLiVE

Janssen’s first-in-class diabetes drug Invokana wins US approval

Will be first SGLT2 inhibitor to reach the market in the States

- PMLiVE

Interview: Cesar Rodriguez, Janssen

Managing director of Janssen UK & Ireland, Cesar Rodriguez is relishing being in the UK market, after years working across Europe and North Africa

EU flag

Five pharma companies begin antibiotic research programme

Sanofi, GSK and AstraZeneca among the collaborators on European projects

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

- PMLiVE

FDA says approval of generic Doxil will ease cancer drug shortage

Allows Sun Pharma to manufacture its own version of the medicine

- PMLiVE

Governments need to “get a grip” on hepatitis C

Janssen-backed report says more needs to be done to tackle the “silent pandemic”

- PMLiVE

Janssen’s Zytiga approved for earlier use in Europe

Prostate cancer drug now licensed for use before chemotherapy

Janssen boosts vaccines pipeline with GlycoVaxyn deal

Research will focus on targeting multiple bacterial pathogens

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Janssen unveils €30,000 prize fund for health tech innovation

Will look for 'transformational ideas' in homecare, adherence and personal health management

Janssen adds Astellas JAK inhibitor to its immunology portfolio

Licenses oral rheumatoid arthritis and psoriasis candidate ASP015K

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links